Inhibition of the ras/raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages 997-1005

  Hong, David S ^a   Cabanillas, Maria E ^b   Wheler, Jennifer ^a   Naing, Aung ^a   Tsimberidou, Apostolia M ^a   Ye, Lei ^b   Waguespack, Steven G ^b   Hernandez, Mike ^b   El Naggar, Alder K ^c   Bidyasar, Savita ^a   Wright, John ^d   Sherman, Steven I ^b   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Division of Cancer Medicine   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN RET; RAF PROTEIN; RAS PROTEIN; SORAFENIB; TIPIFARNIB;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRED VISION; CANCER STAGING; CELLULITIS; CHILL; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DUODENUM PERFORATION; ENZYME INHIBITION; EVENING DOSAGE; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; GENE MUTATION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORNING DOSAGE; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RIGOR; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMACH HEMORRHAGE; SURVIVAL RATE; THROMBOCYTE COUNT; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MALE; MAP KINASE KINASE KINASES; MIDDLE AGED; ONCOGENE PROTEIN P21(RAS); PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; QUINOLONES; RAF KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 79953904634     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1899     Document Type: Article

References (40)

1. Schlumberger M, Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: Patient selection, study design, and recent advances. Thyroid 19:1393-1400
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics, 2008. CA Cancer J Clin 58:71-96 (Pubitemid 351521864)
3. Jemal A,ThunMJ, Ries LA,HoweHL,WeirHK,CenterMM,Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK 2008 Annual report to the nation on the status of cancer, 1975- 2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672-1694
4. Sherman SI, Gillenwater AM 2003 Cancer medicine. Vol. 6. Hamilton, Ontario, Canada: BC Becker
5. TuttleRM,Lukes Y, Onstad L, Lushnikov E, Abrosimov A, Troshin V, Tsyb A, Davis S, Kopecky KJ, Francis G 2008 ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. Thyroid 18:839-846
6. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155-2160 (Pubitemid 16236586)
7. Gottlieb JA, Hill Jr CS 1974 Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193-197
8. Gottlieb JA, Hill Jr CS, Ibanez ML, Clark RL 1972 Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer 30:848-853
9. Boikos SA, Stratakis CA 2008 Molecular mechanisms of medullary thyroid carcinoma: Current approaches in diagnosis and treatment. Histol Histopathol 23:109-116
10. Kelleher FC, McDermottR2008 Response to sunitinib in medullary thyroid cancer. Ann Intern Med 148:567 (Pubitemid 351665439)
11. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713
12. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, HallNC,Wakely Jr PE, Vasko VV, SajiM,Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, ShahMH2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330
13. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
14. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42 (Pubitemid 351931094)
15. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, SunYN,Juan T, Stepan DE, Sherman SI 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801
16. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
17. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, NikiforovYE2003BRAFmutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404 (Pubitemid 37452745)
18. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G 2002 RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370-379 (Pubitemid 34084717)
19. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R 2009 Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15:7061-7068
20. Ratain MJ, Eisen T, StadlerWM,Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512 (Pubitemid 46630627)
21. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R 2009 Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14:95-100
22. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, WilhelmSM,SantoroM2006BAY43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334 (Pubitemid 43338212)
23. Gotlib J 2005 Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 4:77-84
24. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM 2004 Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103:3271-3277 (Pubitemid 38525650)
25. Johnston SR, Semiglazov VF, Manikhas GM, Spaeth D, Romieu G, Dodwell DJ, Wardley AM, Neven P, Bessems A, Park YC, De Porre PM,Perez Ruixo JJ,HowesAJ 2008Aphase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 110:327-335 (Pubitemid 351793882)
26. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A 2007 A phase II trial of tipifarnib in myelofibrosis: Primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 21:1964-1970 (Pubitemid 47299971)
27. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia- Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, KantarjianHM2004 Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287-1292 (Pubitemid 41079843)
28. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J 2001 Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 97:3361-3369
29. Sebti SM 2005 Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7:297-300 (Pubitemid 40544647)
30. Kurzrock R, KantarjianHM,BlascovichMA,Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM 2008 Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res 14:509-514 (Pubitemid 351226120)
31. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, SebtiSM2003 Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: Clinical and biologic activities in the phase 1 setting. Blood 102: 4527-4534 (Pubitemid 37494120)
32. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P 1999 Measuring response in solid tumors: Unidimensional versus bidimensional measurement. J Natl Cancer Inst 91: 523-528 (Pubitemid 29157060)
33. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R 2008 Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7:1001-1006
34. Salgia R, Sherman S, Hong D, Ng C, Frye J, Janisch L, Ratain M, Kurzrock R 2008 A phase I study of XL184, a RET, VEGFR2, and METkinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 26 (Suppl):3522 (Abstract)
35. Lodish MB, Stratakis CA 2008 RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther 8:625-632 (Pubitemid 351818356)
36. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J,MaY, Von HoffD2004 Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438 (Pubitemid 41103625)
37. Runeberg-Roos P, Virtanen H, Saarma M 2007 RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface. Oncogene. 26:7909-7915 (Pubitemid 350261786)
38. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A 2007 R115777 (Zarnestra)/zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 211:533-543 (Pubitemid 46580107)
39. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM 2009 Phase II trial of tipifarnib plus neoadjuvant doxorubicin- cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 15:2942-2948
40. Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Francès C, Knebelmann B, Goldwasser F 2010 Toxicity of sorafenib: Clinical and molecular aspects. Expert Opin Drug Saf 9:275-287